Institutional members access full text with Ovid®

Share this article on:

Cisplatin+Vinorelbine Treatment of Recurrent or Metastatic Salivary Gland Malignancies (RMSGM): A Final Report on 60 Cases

Airoldi, Mario MD; Garzaro, Massimiliano MD; Pedani, Fulvia MD; Ostellino, Oliviero MD; Succo, Giovanni MD; Riva, Giuseppe MD; Sensini, Matteo MD; Naqe, Nertila MD; Bellini, Elisa MD; Raimondo, Luca MD; Pecorari, Giancarlo MD

American Journal of Clinical Oncology: February 2017 - Volume 40 - Issue 1 - p 86–90
doi: 10.1097/COC.0000000000000112
Original Articles: Head and Neck

Objectives: Recurrent or metastatic salivary gland malignancies (RMSGM) are not suitable for conventional treatment. We report the clinical outcomes of 60 patients affected by RMSGM who were treated with DDP+VNB as a first-line or second-line scheme.

Materials and Methods: Sixty patients between 2001 and 2008, affected by RMSGM were enrolled in this cohort prospective study; they received the following first-line or second-line chemotherapy (CT), for a maximum of 6 cycles: DDP at 80 mg/m2 on day 1+VNB at 25 mg/m2 on day 1 and 8, at 3-week intervals.

Results: Seventy percent of the patients received DDP+VNB as the first-line CT and 30% of them received it as the second-line CT. After 5 cycles (median) of first-line DDP+VNB, 7% of the patients achieved a complete response, 24% achieved a partial response, 33% achieved an no change, and 36% achieved a PD. After 4 cycles (median) of second-line CT, 0 patients achieved a CR, 5% achieved a PR, 33% achieved an NC, and 62% achieved a PD. The median overall survival period was 10 months for those who received the first-line CT and 4 months for those who received the second-line CT. The best ORR (54%) and median survival were observed, during first-line treatment, in adenocarcinomas, whereas undifferentiated tumours were unresponsive with a poor median survival (4.6 mo).

Conclusions: Adenocarcinomas show the best response and prognosis with DDP+VNB scheme that seems to be an effective and well-tolerated first-line CT for RMSGM, whereas it has only low palliative activity as a second-line CT.

*2nd Medical Oncology Division, Città della Salute e della Scienza Hospital of Turin

Surgical Sciences Department, 1st ENT Division, University of Turin

ENT Division, Martini Hospital, Turin, Italy

The authors declare no conflicts of interest.

Reprints: Luca Raimondo, MD, Surgical Sciences Department, 1st ENT Division, Surgical Sciences Department, University of Turin, Via Genova, Turin 3—10126, Italy. E-mail:

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.